CAJ | 학술논문

目的：观察培美曲塞二线治疗老年非鳞非小细胞肺癌(NSCLC)的疗效和不良反应。方法：收集我院从2012年7月至2013年4月住院治疗的70岁以上的晚期非鳞NSCLC患者58例并进行疗效和不良反应回顾性分析。患者均为一线化疗失败或不能耐受者。采用培美曲塞500mg ·m-2静脉滴注，每3周1次，共6个周期。结果：本组完全缓解（CR）0例，部分缓解（PR）6例，疾病稳定（SD）20例，SD持续时间大于6个月的12例，疾病进展（PD）32例。总有效率（RR=CR+PR）为10.3％，临床获益率(CR+PR+SD>6个月)为31.0%，中位无疾病进展时间（PFS）为3.4个月（2.0～8.9个月）。完成6周期治疗的患者10例。主要毒性反应为骨髓抑制、胃肠反应和疲劳。结论：70岁以上的、一线化疗失败的非鳞NSCLC患者能从二线培美曲塞治疗中获益，耐受性良好。
목적：관찰배미곡새이선치료노년비린비소세포폐암(NSCLC)적료효화불량반응。방법：수집아원종2012년7월지2013년4월주원치료적70세이상적만기비린NSCLC환자58례병진행료효화불량반응회고성분석。환자균위일선화료실패혹불능내수자。채용배미곡새500mg ·m-2정맥적주，매3주1차，공6개주기。결과：본조완전완해（CR）0례，부분완해（PR）6례，질병은정（SD）20례，SD지속시간대우6개월적12례，질병진전（PD）32례。총유효솔（RR=CR+PR）위10.3％，림상획익솔(CR+PR+SD>6개월)위31.0%，중위무질병진전시간（PFS）위3.4개월（2.0～8.9개월）。완성6주기치료적환자10례。주요독성반응위골수억제、위장반응화피로。결론：70세이상적、일선화료실패적비린NSCLC환자능종이선배미곡새치료중획익，내수성량호。
Objective: To investigate the efficacy and safety of pemetrexed as the second-line therapy in patients older than 70 years with advanced non-squamous non-smal cel lung cancer . Methods: In a single-centre , pemetrexed as the second-line therapy trial , a total of 58 patients older than 70 years with advanced non-squamous non-smal cel lung cancer,failed in their first-line treatment because of progressive disease or severe adverse events, were assigned to receive pemetrexed 500mg/m2 every 3 week, iv, for 6 cycles. Results:Complete remission (CR) occurred in 0 patients, partial remissions (PR) in 6 patients, stable diseases (SD) in 20 patients, SD lasting more than 6 months in 12 patients and progressive diseases (PD) in 32 patients. total response rate (RR) occurred in 10.3%of patients, and clinical benefit (CR+PR+SD>6 months) 31.0%. The median progression free survival (PFS) was 3.4 (2-8.9) months. Ten patients completed 6-cycle treatment. Predominant toxicity were neutropenia , nausea and fatigue. Conclusion: Pemetrexed as second-line therapy appears to be an efficient and wel-tolerated regimen in patients older than 70 years with advanced non-squamous non-smal cel lung cancer .